NCT01389609View on ClinicalTrials.gov

Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Hypertension
Interventions
DRUG

Doxazosin 4 mg Japanese marketed IR tablet

Immediate release tablet, 4 mg, single dose

DRUG

Doxazosin 4 mg ODT with water

Orally-disintegrating Tablet , 4 mg, single dose with water

DRUG

Doxazosin 4 mg ODT without water

Orally-disintegrating Tablet , 4 mg, single dose without water

Trial Locations (1)

Unknown

Pfizer Investigational Site, Shinjuku-ku

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01389609 - Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition | Biotech Hunter | Biotech Hunter